| Name | Crism Therapeutics Corporation Ord Npv |
|---|---|
| Epic | CRTX |
| Isin | VGG042401262 |
| Index | AIM100 AIM350 |
| Industry | Open End and Miscellaneous Investment Vehicles |
| Latest share price | 9.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2.94 | Debt ratio | n/a |
| Shares in issue | 32.68 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | 1.80p | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -57.98 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.17 | 52-week high / low | 8.50p / 18.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Special | 2023-06-01 | 2023-06-14 | 1.80p |
| Company name | Crism Therapeutics Corporation Ord Npv |
|---|---|
| Address | Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands, USA |
| Telephone | +1 (925) 408 4621 |
| Website | http://www.crismtherapeutics.com/ |
| Director | Position |
|---|---|
| Mr Andrew James Webb | CEO |
| Dr Nermeen Yunus Varawalla | Non-Executive Chairman |
| Mr Gerald Beaney | Independent Non-Executive Director |
| Mr Christopher McConville | Chief Scientific Officer |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | n/a | n/a | n/a |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.4 | 0.06 | 0.11 |
| Cash and equivalents | 4.38 | 3.48 | 6.68 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 4.79 | 28.74 | 31.24 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.66 | 0.75 | 0.97 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | 0.18 | 0.16 |
| Total of all liabilities | 0.66 | 0.92 | 1.13 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 4.12 | 27.82 | 30.11 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 80.79 | 80.79 | 80.45 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -80.95 | -40.53 | -37.52 |
| Share premium account | 4.28 | 4.28 | 4.28 |
| Total equity | 4.12 | 27.82 | 30.11 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.26 | -2.6 | -1.79 |
| Pre-tax profit | -2.39 | -2.6 | -1.79 |